VAQTA VACCINE 25 u0.5 ml

Riik: Singapur

keel: inglise

Allikas: HSA (Health Sciences Authority)

Toimeaine:

HEPATITIS A VIRUS (INACTIVATED)

Saadav alates:

MSD PHARMA (SINGAPORE) PTE. LTD.

ATC kood:

J07BC02

Annus:

25 u/0.5 ml

Ravimvorm:

INJECTION

Koostis:

HEPATITIS A VIRUS (INACTIVATED) 25 u/0.5 ml

Manustamisviis:

INTRAMUSCULAR

Retsepti tüüp:

Prescription Only

Valmistatud:

Merck Sharp & Dohme LLC

Volitamisolek:

ACTIVE

Loa andmise kuupäev:

1998-09-17

Infovoldik

SG-VAQ-I-072011 

PRODUCT 
CIRCULAR 

_ _
VAQTA
®

[HEPATITIS A VACCINE, PURIFIED INACTIVATED, MSD] 

I. THERAPEUTIC 
CLASS 

VAQTA is an inactivated whole virus vaccine which has been shown to
induce antibody to 
hepatitis A virus protein.   

II. INDICATIONS 

VAQTA is indicated for active pre-exposure prophylaxis against disease
caused by HAV. 
VAQTA is recommended for healthy individuals from 12 months of age and
older who are at risk 
of contracting or spreading infection or who are at risk
of life-threatening disease if infected 
(e.g., hepatitis C with diagnosed liver disease, adults with
Human Immunodeficiency Virus 
[HIV]). 

III. 
DOSAGE AND ADMINISTRATION

DO NOT INJECT INTRAVASCULARLY OR INTRADERMALLY. 

VAQTA is for intramuscular injection. For adults, adolescents, and
children older than 2 years of 
age, the deltoid muscle is the preferred site for intramuscular
injection. For children 12 through 
23 months of age, the anterolateral area of the thigh is the preferred
site for intramuscular 
injection.  

Adults with Bleeding Disorders 
For individuals with bleeding disorders who are at risk
of hemorrhage following intramuscular 
injection (e.g., hemophiliacs), this vaccine can be administered
subcutaneously (See 
PRECAUTIONS).  

The vaccination series consists of one primary dose and one booster
dose given according to 
the following schedule: 

_Children/Adolescents – 12 Months Through 17 Years of Age _
Individuals 12 months through 17 years of age should receive a single
0.5 mL (~25U) dose of 
vaccine at elected date and a booster dose of 0.5 mL (~25U) 6 to 18
months later. 

_Adults_ 
Adults 18 years of age and older should receive a single 1.0
mL (~50U) dose of vaccine at 
elected date and a booster dose of 1.0
mL (~50U) 6 to 18 months later.

_Adults With Human Immunodeficiency Virus (HIV)  _
HIV-infected adults should receive a single 1.0 mL (~50U)

Toote omadused

SG-VAQ-I-072011
PRODUCT CIRCULAR
VAQTA®
[Hepatitis A Vaccine, Purified Inactivated, MSD]
I.
THERAPEUTIC CLASS
VAQTA is an inactivated whole virus vaccine which has been shown to
induce antibody to
hepatitis A virus protein.
II.
INDICATIONS
VAQTA is indicated for active pre-exposure prophylaxis against disease
caused by HAV.
VAQTA is recommended for healthy individuals from 12 months of age and
older who are at risk
of contracting or spreading infection or who are at risk of
life-threatening disease if infected (e.g.,
hepatitis C with diagnosed liver disease, adults with Human
Immunodeficiency Virus [HIV]).
III.
DOSAGE AND ADMINISTRATION
DO NOT INJECT INTRAVASCULARLY OR INTRADERMALLY
VAQTA is for intramuscular injection. For adults, adolescents, and
children older than 2 years of
age, the deltoid muscle is the preferred site for intramuscular
injection. For children 12 through
23 months of age, the anterolateral area of the thigh is the preferred
site for intramuscular
injection.
Adults with Bleeding Disorders
For individuals with bleeding disorders who are at risk of hemorrhage
following intramuscular
injection
(e.g.,
hemophiliacs),
this
vaccine
can
be
administered
subcutaneously
(See
PRECAUTIONS).
The vaccination series consists of one primary dose and one booster
dose given according to
the following schedule:
Children/Adolescents – 12 Months Through 17 Years of Age
Individuals 12 months through 17 years of age should receive a single
0.5 mL (~25 U) dose of
vaccine at elected date and a booster dose of 0.5 mL (~25 U) 6 to 18
months later.
Adults
Adults 18 years of age and older should receive a single 1.0 mL (~50
U) dose of vaccine at
elected date and a booster dose of 1.0 mL (~50 U) 6 to 18 months
later.
Adults With Human Immunodeficiency Virus (HIV)
HIV-infected adults should receive a single 1.0 mL (~50 U) dose of
vaccine at elected date and
a booster dose of 1.0 mL (~50 U) 6 months later.
Interchangeability of the Booster Dose
A booster dose of VAQTA may be given at 6 to 12 months following the
initial d